DR   Wikidata; Q54900012
RX   PubMed=25998688;
CC   Problematic cell line: Contaminated. Parent cell line (KKU-213B) shown to be a KKU-M213 derivative.
CC   Population: Southeast Asian; Thai.
CC   Doubling time: 25.21 +- 1.88 hours (PubMed=25998688).
CC   Selected for resistance to: ChEBI; CHEBI:175901; Gemcitabine (Gemzar).
CC   Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Cys (c.37G>T); ClinVar=VCV000045123; Zygosity=Unspecified (from parent cell line).
CC   Derived from site: In situ; Liver; UBERON=UBERON_0002107.
DI   NCIt; C35417; Intrahepatic cholangiocarcinoma
DI   NCIt; C27769; Opisthorchis viverrini-related cholangiocarcinoma
DI   ORDO; Orphanet_70567; Cholangiocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_M264 ! KKU-213B
SX   Male
AG   58Y
CA   Cancer cell line
DT   Created: 01-12-16; Last updated: 29-06-23; Version: 10
RX   PubMed=25998688; DOI=10.3892/ijo.2015.3019;
RA   Wattanawongdon W., Hahnvajanawong C., Namwat N., Kanchanawat S.,
RA   Boonmars T., Jearanaikoon P., Leelayuwat C., Techasen A., Seubwai W.;
RT   "Establishment and characterization of gemcitabine-resistant human
RT   cholangiocarcinoma cell lines with multidrug resistance and enhanced
RT   invasiveness.";
RL   Int. J. Oncol. 47:398-410(2015).